The US Food and Drug Administration has approved the use of the biological medicine frunevetmab to treat pain in cats suffering from osteoarthritis. It is the first of its kind to be approved by the FDA for use in an animal species.
In osteoarthritis, the articular cartilage is damaged. Bones in a joint rub against each other, causing pain, reduced mobility, and over time, formation of bone spurs or other changes in and around the joint.
Frunevetmab is a cat-specific monoclonal antibody capable of recognizing and attaching to nerve growth factor (NGF) that is involved in the regulation of pain. When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.
The...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
